Matt Kiely Named UK General Manager at Genmab to Propel Oncology Innovations

Genmab, a prominent biotech company specialising in antibody science, has appointed Matt Kiely as General Manager for the UK. This strategic move supports Genmab’s expansion in Europe, aiming to broaden patient access to its innovative cancer therapies. Kiely, a veteran in pharmaceutical leadership, commences his role on September 1. 

Founded in 1999 with headquarters in Copenhagen, Genmab has earned recognition for its antibody-based therapeutic innovations. With its commercial expansion efforts now targeting the UK, Matt Kiely’s expertise in oncology and market access is expected to significantly drive Genmab’s initiatives. His background with firms like GSK and Takeda highlights his capacity to build successful commercialisation strategies. The UK market holds promising opportunities for Genmab, as it is poised to improve cancer treatment access via its advanced medicines.